康希诺生物(06185): Hib疫苗获批准开展临床试验，重组肺炎球菌蛋白疫苗I期试验见成效

和讯网04-23

快讯正文【康希诺生物冻干Hib疫苗获国家药监局批准开展临床试验】康希诺生物股价今日大涨，最高涨幅接近6%。截至发稿时，公司股价攀升4.69%，报收于18.32港元，成交额达到830.79万港元。根据公司公告，康希诺生物研发的冻干b型流感嗜血杆菌（Hib）结合疫苗已成功获得国家药监局的批准，即将展开相关临床试验。此外，该公司近期还公布了其研发的重组肺炎球菌蛋白疫苗在I期临床试验（包括Ia期及Ib期）...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2429307971?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-23 13:10","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2429307971","market":"hk","top_or_hot":-1,"title":"康希诺生物(06185): Hib疫苗获批准开展临床试验，重组肺炎球菌蛋白疫苗I期试验见成效","media":"和讯网","content":"<div>\n<p>快讯正文【康希诺生物冻干Hib疫苗获国家药监局批准开展临床试验】康希诺生物股价今日大涨，最高涨幅接近6%。截至发稿时，公司股价攀升4.69%，报收于18.32港元，成交额达到830.79万港元。根据公司公告，康希诺生物研发的冻干b型流感嗜血杆菌（Hib）结合疫苗已成功获得国家药监局的批准，即将展开相关临床试验。此外，该公司近期还公布了其研发的重组肺炎球菌蛋白疫苗在I期临床试验（包括Ia期及Ib期）...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313424387a467ba&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康希诺生物(06185): Hib疫苗获批准开展临床试验，重组肺炎球菌蛋白疫苗I期试验见成效</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康希诺生物(06185): Hib疫苗获批准开展临床试验，重组肺炎球菌蛋白疫苗I期试验见成效\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-23 13:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313424387a467ba&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>快讯正文【康希诺生物冻干Hib疫苗获国家药监局批准开展临床试验】康希诺生物股价今日大涨，最高涨幅接近6%。截至发稿时，公司股价攀升4.69%，报收于18.32港元，成交额达到830.79万港元。根据公司公告，康希诺生物研发的冻干b型流感嗜血杆菌（Hib）结合疫苗已成功获得国家药监局的批准，即将展开相关临床试验。此外，该公司近期还公布了其研发的重组肺炎球菌蛋白疫苗在I期临床试验（包括Ia期及Ib期）...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313424387a467ba&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03347","symbol_name":"泰格医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313424387a467ba&s=b","article_id":"2429307971","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313424387a467ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2429307971","pubTimestamp":1713849045,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"快讯正文康希诺生物股价今日大涨，最高涨幅接近6%。截至发稿时，公司股价攀升4.69%，报收于18.32港元，成交额达到830.79万港元。根据公司公告，康希诺生物研发的冻干b型流感嗜血杆菌结合疫苗已成功获得国家药监局的批准，即将展开相关临床试验。此外，该公司近期还公布了其研发的重组肺炎球菌蛋白疫苗在I期临床试验中取得的积极初步结果。基于I期临床试验的初步成果，康希诺生物计划进行下一阶段的PBPV研发工作评估与规划。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688185":"康希诺","03347":"泰格医药","BK1583":"高瓴概念","BK1576":"医药外包概念","BK1574":"生物医药B类股","06185":"康希诺生物","BK1191":"制药","BK1515":"抗疫概念","BK1141":"生命科学工具和服务","BK1161":"生物科技"},"translate_title":"CanSino Biologics (06185): Hib vaccine approved for clinical trials, phase I trial of recombinant pneumococcal protein vaccine has achieved results","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":0.9,"03347":1,"06185":1},"content_text":"快讯正文【康希诺生物冻干Hib疫苗获国家药监局批准开展临床试验】康希诺生物股价今日大涨，最高涨幅接近6%。截至发稿时，公司股价攀升4.69%，报收于18.32港元，成交额达到830.79万港元。根据公司公告，康希诺生物研发的冻干b型流感嗜血杆菌（Hib）结合疫苗已成功获得国家药监局的批准，即将展开相关临床试验。此外，该公司近期还公布了其研发的重组肺炎球菌蛋白疫苗在I期临床试验（包括Ia期及Ib期）中取得的积极初步结果。基于I期临床试验的初步成果，康希诺生物计划进行下一阶段的PBPV研发工作评估与规划。投资者可密切关注该公司的后续研发进展及其对公司股价的潜在影响。下载和讯APP查看快讯，体验更佳>>","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429307971"}